chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 91.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, COVID-19 pneumonia, Carbon dioxide decreased, Cardiac telemetry, Chest X-ray abnormal
Clinical narrative: /Narrative: Pt presented to ED on 9/27/2022 c/o cough with yellow mucous and chest congestion x 1 week; + sick contact exposure. In the ED, the pt was tachypnic. COVID-19 swab was positive. CXR showed elevated right diaphragm and possible right lower lobe atelectasis. Pt admitted 9/27/22-9/30/22 with priniple diagnosis: PRINCIPAL DIAGNOSIS: 1. New Onset of Shortness of Breath with Productive Cough, Tachypnea & Tachycardia 2/2 COVID-19 Viral Syndrome 2. Acute Respiratory Failure with Hypoxia & Hypocapnia 2/2 Covid-19 Viral Pneumonia 3. Acute Tachycardia & Tachypnea in Setting of Acute on Chronic Atrial Fibrillation w/ Flutter, Occasional Rapid Response on Apixaban 4. Acute on Chronic Normocytic Anemia 5. Acute on Chronic Kidney Disease Stage 4 6. Hyperkalemia 7. Hyperchloremia ADDITIONAL DIAGNSES: 8. BPH 9. Hypertension 10. Hx Prostate Cancer 11. Depression 12. Type II diabetes, Diet Controlled 13. GERD 14. Obesity Class 2: BMI 34.0 Hosp. Course includes: Patient's chief symptoms on admission were; hypoxia requiring supplemental oxygen therapy, hypocapnea, tachycardia and tachypnea. Patient noted on file- Moderna vaccination x 3 doses. Supportive care and monitoring implemented; screening/trend labs, EKGs and imaging studies. EKGs obtained during this hospitalization, noted with Atrial flutter with variable A-V block with PVCs. Pt is on chronic anticoagulation with apixiban for management of chronic Atrial Flutter. CXR obtained-impression negative for cardiopulmonary and elevated right diaphragm and possible right lower lobe atelectasis. No evidence of superimposed bacterial pneumonia. Airborne Precautions initiated. COVID-19 viral pneumonia treatment was initiated with ; dexamethasone 6mg qd, PRN acetaminophen/tesselon/albuterol inhaler, continous pox, telemetry monitoring, PRN supplementation of electrolytes, consults, etc. Patient noted with respiratory alkalosis; CO2 levels ranged between 15-20 mmol/L - treated with sodium bicarbonate supplementation of 1300mg oral twice a day for management. Patient did not require remdesivir. Patient considered for discharge on 9/29/22, and initially no labs were obtained. In preparing medication reconcillation, unable to determine if sodium bicarbonate should be ordered on discharge. There fore, ordered a CHEM7 at 13:00 on 9/29/2022. CHEM7 resulted, most notable for hyperkalemia (K+ level of 5.80) and Scr 2.2/BUN 40. NO hemolysis noted on lab report. Discharge cancelled for management of hyperkalemia. One dose of Patiromer Calcium Sorbitex 8.4gm/1PKT was ordered and administered. Telemetry monitoring restarted, EKG obtained at this time(results - Aflutter with variable A-V block, ST & Twave abnormality), initiated IVF hydration w/ NS @ 75cc/hr and cardiac enzymes ordered. On following day (9/30/22), Pt denied any acute concerns or pain, K+ level; 5.0, Scr 2.2 and cardiac enzyme set of 3 negative for troponin elevation. Patient was cleared for discharge to home with family at this time- on 9/30/22.
Age: 91.0
Sex: M
Vaccine: COVID19
Symptoms: Chronic kidney disease, Condition aggravated, Dyspnoea, Electrocardiogram ST-T segment abnormal, Electrocardiogram abnormal
Clinical narrative: /Narrative: Pt presented to ED on 9/27/2022 c/o cough with yellow mucous and chest congestion x 1 week; + sick contact exposure. In the ED, the pt was tachypnic. COVID-19 swab was positive. CXR showed elevated right diaphragm and possible right lower lobe atelectasis. Pt admitted 9/27/22-9/30/22 with priniple diagnosis: PRINCIPAL DIAGNOSIS: 1. New Onset of Shortness of Breath with Productive Cough, Tachypnea & Tachycardia 2/2 COVID-19 Viral Syndrome 2. Acute Respiratory Failure with Hypoxia & Hypocapnia 2/2 Covid-19 Viral Pneumonia 3. Acute Tachycardia & Tachypnea in Setting of Acute on Chronic Atrial Fibrillation w/ Flutter, Occasional Rapid Response on Apixaban 4. Acute on Chronic Normocytic Anemia 5. Acute on Chronic Kidney Disease Stage 4 6. Hyperkalemia 7. Hyperchloremia ADDITIONAL DIAGNSES: 8. BPH 9. Hypertension 10. Hx Prostate Cancer 11. Depression 12. Type II diabetes, Diet Controlled 13. GERD 14. Obesity Class 2: BMI 34.0 Hosp. Course includes: Patient's chief symptoms on admission were; hypoxia requiring supplemental oxygen therapy, hypocapnea, tachycardia and tachypnea. Patient noted on file- Moderna vaccination x 3 doses. Supportive care and monitoring implemented; screening/trend labs, EKGs and imaging studies. EKGs obtained during this hospitalization, noted with Atrial flutter with variable A-V block with PVCs. Pt is on chronic anticoagulation with apixiban for management of chronic Atrial Flutter. CXR obtained-impression negative for cardiopulmonary and elevated right diaphragm and possible right lower lobe atelectasis. No evidence of superimposed bacterial pneumonia. Airborne Precautions initiated. COVID-19 viral pneumonia treatment was initiated with ; dexamethasone 6mg qd, PRN acetaminophen/tesselon/albuterol inhaler, continous pox, telemetry monitoring, PRN supplementation of electrolytes, consults, etc. Patient noted with respiratory alkalosis; CO2 levels ranged between 15-20 mmol/L - treated with sodium bicarbonate supplementation of 1300mg oral twice a day for management. Patient did not require remdesivir. Patient considered for discharge on 9/29/22, and initially no labs were obtained. In preparing medication reconcillation, unable to determine if sodium bicarbonate should be ordered on discharge. There fore, ordered a CHEM7 at 13:00 on 9/29/2022. CHEM7 resulted, most notable for hyperkalemia (K+ level of 5.80) and Scr 2.2/BUN 40. NO hemolysis noted on lab report. Discharge cancelled for management of hyperkalemia. One dose of Patiromer Calcium Sorbitex 8.4gm/1PKT was ordered and administered. Telemetry monitoring restarted, EKG obtained at this time(results - Aflutter with variable A-V block, ST & Twave abnormality), initiated IVF hydration w/ NS @ 75cc/hr and cardiac enzymes ordered. On following day (9/30/22), Pt denied any acute concerns or pain, K+ level; 5.0, Scr 2.2 and cardiac enzyme set of 3 negative for troponin elevation. Patient was cleared for discharge to home with family at this time- on 9/30/22.
Age: 91.0
Sex: M
Vaccine: COVID19
Symptoms: Eosinophil count decreased, Eosinophil percentage decreased, Exposure to SARS-CoV-2, Glomerular filtration rate decreased, Granulocyte count
Clinical narrative: /Narrative: Pt presented to ED on 9/27/2022 c/o cough with yellow mucous and chest congestion x 1 week; + sick contact exposure. In the ED, the pt was tachypnic. COVID-19 swab was positive. CXR showed elevated right diaphragm and possible right lower lobe atelectasis. Pt admitted 9/27/22-9/30/22 with priniple diagnosis: PRINCIPAL DIAGNOSIS: 1. New Onset of Shortness of Breath with Productive Cough, Tachypnea & Tachycardia 2/2 COVID-19 Viral Syndrome 2. Acute Respiratory Failure with Hypoxia & Hypocapnia 2/2 Covid-19 Viral Pneumonia 3. Acute Tachycardia & Tachypnea in Setting of Acute on Chronic Atrial Fibrillation w/ Flutter, Occasional Rapid Response on Apixaban 4. Acute on Chronic Normocytic Anemia 5. Acute on Chronic Kidney Disease Stage 4 6. Hyperkalemia 7. Hyperchloremia ADDITIONAL DIAGNSES: 8. BPH 9. Hypertension 10. Hx Prostate Cancer 11. Depression 12. Type II diabetes, Diet Controlled 13. GERD 14. Obesity Class 2: BMI 34.0 Hosp. Course includes: Patient's chief symptoms on admission were; hypoxia requiring supplemental oxygen therapy, hypocapnea, tachycardia and tachypnea. Patient noted on file- Moderna vaccination x 3 doses. Supportive care and monitoring implemented; screening/trend labs, EKGs and imaging studies. EKGs obtained during this hospitalization, noted with Atrial flutter with variable A-V block with PVCs. Pt is on chronic anticoagulation with apixiban for management of chronic Atrial Flutter. CXR obtained-impression negative for cardiopulmonary and elevated right diaphragm and possible right lower lobe atelectasis. No evidence of superimposed bacterial pneumonia. Airborne Precautions initiated. COVID-19 viral pneumonia treatment was initiated with ; dexamethasone 6mg qd, PRN acetaminophen/tesselon/albuterol inhaler, continous pox, telemetry monitoring, PRN supplementation of electrolytes, consults, etc. Patient noted with respiratory alkalosis; CO2 levels ranged between 15-20 mmol/L - treated with sodium bicarbonate supplementation of 1300mg oral twice a day for management. Patient did not require remdesivir. Patient considered for discharge on 9/29/22, and initially no labs were obtained. In preparing medication reconcillation, unable to determine if sodium bicarbonate should be ordered on discharge. There fore, ordered a CHEM7 at 13:00 on 9/29/2022. CHEM7 resulted, most notable for hyperkalemia (K+ level of 5.80) and Scr 2.2/BUN 40. NO hemolysis noted on lab report. Discharge cancelled for management of hyperkalemia. One dose of Patiromer Calcium Sorbitex 8.4gm/1PKT was ordered and administered. Telemetry monitoring restarted, EKG obtained at this time(results - Aflutter with variable A-V block, ST & Twave abnormality), initiated IVF hydration w/ NS @ 75cc/hr and cardiac enzymes ordered. On following day (9/30/22), Pt denied any acute concerns or pain, K+ level; 5.0, Scr 2.2 and cardiac enzyme set of 3 negative for troponin elevation. Patient was cleared for discharge to home with family at this time- on 9/30/22.
Age: 91.0
Sex: M
Vaccine: COVID19
Symptoms: Granulocyte percentage, Haematocrit decreased, Haemoglobin decreased, Hyperchloraemia, Hyperkalaemia
Clinical narrative: /Narrative: Pt presented to ED on 9/27/2022 c/o cough with yellow mucous and chest congestion x 1 week; + sick contact exposure. In the ED, the pt was tachypnic. COVID-19 swab was positive. CXR showed elevated right diaphragm and possible right lower lobe atelectasis. Pt admitted 9/27/22-9/30/22 with priniple diagnosis: PRINCIPAL DIAGNOSIS: 1. New Onset of Shortness of Breath with Productive Cough, Tachypnea & Tachycardia 2/2 COVID-19 Viral Syndrome 2. Acute Respiratory Failure with Hypoxia & Hypocapnia 2/2 Covid-19 Viral Pneumonia 3. Acute Tachycardia & Tachypnea in Setting of Acute on Chronic Atrial Fibrillation w/ Flutter, Occasional Rapid Response on Apixaban 4. Acute on Chronic Normocytic Anemia 5. Acute on Chronic Kidney Disease Stage 4 6. Hyperkalemia 7. Hyperchloremia ADDITIONAL DIAGNSES: 8. BPH 9. Hypertension 10. Hx Prostate Cancer 11. Depression 12. Type II diabetes, Diet Controlled 13. GERD 14. Obesity Class 2: BMI 34.0 Hosp. Course includes: Patient's chief symptoms on admission were; hypoxia requiring supplemental oxygen therapy, hypocapnea, tachycardia and tachypnea. Patient noted on file- Moderna vaccination x 3 doses. Supportive care and monitoring implemented; screening/trend labs, EKGs and imaging studies. EKGs obtained during this hospitalization, noted with Atrial flutter with variable A-V block with PVCs. Pt is on chronic anticoagulation with apixiban for management of chronic Atrial Flutter. CXR obtained-impression negative for cardiopulmonary and elevated right diaphragm and possible right lower lobe atelectasis. No evidence of superimposed bacterial pneumonia. Airborne Precautions initiated. COVID-19 viral pneumonia treatment was initiated with ; dexamethasone 6mg qd, PRN acetaminophen/tesselon/albuterol inhaler, continous pox, telemetry monitoring, PRN supplementation of electrolytes, consults, etc. Patient noted with respiratory alkalosis; CO2 levels ranged between 15-20 mmol/L - treated with sodium bicarbonate supplementation of 1300mg oral twice a day for management. Patient did not require remdesivir. Patient considered for discharge on 9/29/22, and initially no labs were obtained. In preparing medication reconcillation, unable to determine if sodium bicarbonate should be ordered on discharge. There fore, ordered a CHEM7 at 13:00 on 9/29/2022. CHEM7 resulted, most notable for hyperkalemia (K+ level of 5.80) and Scr 2.2/BUN 40. NO hemolysis noted on lab report. Discharge cancelled for management of hyperkalemia. One dose of Patiromer Calcium Sorbitex 8.4gm/1PKT was ordered and administered. Telemetry monitoring restarted, EKG obtained at this time(results - Aflutter with variable A-V block, ST & Twave abnormality), initiated IVF hydration w/ NS @ 75cc/hr and cardiac enzymes ordered. On following day (9/30/22), Pt denied any acute concerns or pain, K+ level; 5.0, Scr 2.2 and cardiac enzyme set of 3 negative for troponin elevation. Patient was cleared for discharge to home with family at this time- on 9/30/22.
Age: 91.0
Sex: M
Vaccine: COVID19
Symptoms: Hypocapnia, Hypoxia, Laboratory test, Lymphocyte count, Lymphocyte percentage decreased
Clinical narrative: /Narrative: Pt presented to ED on 9/27/2022 c/o cough with yellow mucous and chest congestion x 1 week; + sick contact exposure. In the ED, the pt was tachypnic. COVID-19 swab was positive. CXR showed elevated right diaphragm and possible right lower lobe atelectasis. Pt admitted 9/27/22-9/30/22 with priniple diagnosis: PRINCIPAL DIAGNOSIS: 1. New Onset of Shortness of Breath with Productive Cough, Tachypnea & Tachycardia 2/2 COVID-19 Viral Syndrome 2. Acute Respiratory Failure with Hypoxia & Hypocapnia 2/2 Covid-19 Viral Pneumonia 3. Acute Tachycardia & Tachypnea in Setting of Acute on Chronic Atrial Fibrillation w/ Flutter, Occasional Rapid Response on Apixaban 4. Acute on Chronic Normocytic Anemia 5. Acute on Chronic Kidney Disease Stage 4 6. Hyperkalemia 7. Hyperchloremia ADDITIONAL DIAGNSES: 8. BPH 9. Hypertension 10. Hx Prostate Cancer 11. Depression 12. Type II diabetes, Diet Controlled 13. GERD 14. Obesity Class 2: BMI 34.0 Hosp. Course includes: Patient's chief symptoms on admission were; hypoxia requiring supplemental oxygen therapy, hypocapnea, tachycardia and tachypnea. Patient noted on file- Moderna vaccination x 3 doses. Supportive care and monitoring implemented; screening/trend labs, EKGs and imaging studies. EKGs obtained during this hospitalization, noted with Atrial flutter with variable A-V block with PVCs. Pt is on chronic anticoagulation with apixiban for management of chronic Atrial Flutter. CXR obtained-impression negative for cardiopulmonary and elevated right diaphragm and possible right lower lobe atelectasis. No evidence of superimposed bacterial pneumonia. Airborne Precautions initiated. COVID-19 viral pneumonia treatment was initiated with ; dexamethasone 6mg qd, PRN acetaminophen/tesselon/albuterol inhaler, continous pox, telemetry monitoring, PRN supplementation of electrolytes, consults, etc. Patient noted with respiratory alkalosis; CO2 levels ranged between 15-20 mmol/L - treated with sodium bicarbonate supplementation of 1300mg oral twice a day for management. Patient did not require remdesivir. Patient considered for discharge on 9/29/22, and initially no labs were obtained. In preparing medication reconcillation, unable to determine if sodium bicarbonate should be ordered on discharge. There fore, ordered a CHEM7 at 13:00 on 9/29/2022. CHEM7 resulted, most notable for hyperkalemia (K+ level of 5.80) and Scr 2.2/BUN 40. NO hemolysis noted on lab report. Discharge cancelled for management of hyperkalemia. One dose of Patiromer Calcium Sorbitex 8.4gm/1PKT was ordered and administered. Telemetry monitoring restarted, EKG obtained at this time(results - Aflutter with variable A-V block, ST & Twave abnormality), initiated IVF hydration w/ NS @ 75cc/hr and cardiac enzymes ordered. On following day (9/30/22), Pt denied any acute concerns or pain, K+ level; 5.0, Scr 2.2 and cardiac enzyme set of 3 negative for troponin elevation. Patient was cleared for discharge to home with family at this time- on 9/30/22.
Age: 91.0
Sex: M
Vaccine: COVID19
Symptoms: Monocyte percentage increased, Myocardial necrosis marker, Normocytic anaemia, Platelet count normal, Productive cough
Clinical narrative: /Narrative: Pt presented to ED on 9/27/2022 c/o cough with yellow mucous and chest congestion x 1 week; + sick contact exposure. In the ED, the pt was tachypnic. COVID-19 swab was positive. CXR showed elevated right diaphragm and possible right lower lobe atelectasis. Pt admitted 9/27/22-9/30/22 with priniple diagnosis: PRINCIPAL DIAGNOSIS: 1. New Onset of Shortness of Breath with Productive Cough, Tachypnea & Tachycardia 2/2 COVID-19 Viral Syndrome 2. Acute Respiratory Failure with Hypoxia & Hypocapnia 2/2 Covid-19 Viral Pneumonia 3. Acute Tachycardia & Tachypnea in Setting of Acute on Chronic Atrial Fibrillation w/ Flutter, Occasional Rapid Response on Apixaban 4. Acute on Chronic Normocytic Anemia 5. Acute on Chronic Kidney Disease Stage 4 6. Hyperkalemia 7. Hyperchloremia ADDITIONAL DIAGNSES: 8. BPH 9. Hypertension 10. Hx Prostate Cancer 11. Depression 12. Type II diabetes, Diet Controlled 13. GERD 14. Obesity Class 2: BMI 34.0 Hosp. Course includes: Patient's chief symptoms on admission were; hypoxia requiring supplemental oxygen therapy, hypocapnea, tachycardia and tachypnea. Patient noted on file- Moderna vaccination x 3 doses. Supportive care and monitoring implemented; screening/trend labs, EKGs and imaging studies. EKGs obtained during this hospitalization, noted with Atrial flutter with variable A-V block with PVCs. Pt is on chronic anticoagulation with apixiban for management of chronic Atrial Flutter. CXR obtained-impression negative for cardiopulmonary and elevated right diaphragm and possible right lower lobe atelectasis. No evidence of superimposed bacterial pneumonia. Airborne Precautions initiated. COVID-19 viral pneumonia treatment was initiated with ; dexamethasone 6mg qd, PRN acetaminophen/tesselon/albuterol inhaler, continous pox, telemetry monitoring, PRN supplementation of electrolytes, consults, etc. Patient noted with respiratory alkalosis; CO2 levels ranged between 15-20 mmol/L - treated with sodium bicarbonate supplementation of 1300mg oral twice a day for management. Patient did not require remdesivir. Patient considered for discharge on 9/29/22, and initially no labs were obtained. In preparing medication reconcillation, unable to determine if sodium bicarbonate should be ordered on discharge. There fore, ordered a CHEM7 at 13:00 on 9/29/2022. CHEM7 resulted, most notable for hyperkalemia (K+ level of 5.80) and Scr 2.2/BUN 40. NO hemolysis noted on lab report. Discharge cancelled for management of hyperkalemia. One dose of Patiromer Calcium Sorbitex 8.4gm/1PKT was ordered and administered. Telemetry monitoring restarted, EKG obtained at this time(results - Aflutter with variable A-V block, ST & Twave abnormality), initiated IVF hydration w/ NS @ 75cc/hr and cardiac enzymes ordered. On following day (9/30/22), Pt denied any acute concerns or pain, K+ level; 5.0, Scr 2.2 and cardiac enzyme set of 3 negative for troponin elevation. Patient was cleared for discharge to home with family at this time- on 9/30/22.
Age: 91.0
Sex: M
Vaccine: COVID19
Symptoms: Secretion discharge, Tachycardia, Tachypnoea, Troponin normal, Ventricular extrasystoles
Clinical narrative: /Narrative: Pt presented to ED on 9/27/2022 c/o cough with yellow mucous and chest congestion x 1 week; + sick contact exposure. In the ED, the pt was tachypnic. COVID-19 swab was positive. CXR showed elevated right diaphragm and possible right lower lobe atelectasis. Pt admitted 9/27/22-9/30/22 with priniple diagnosis: PRINCIPAL DIAGNOSIS: 1. New Onset of Shortness of Breath with Productive Cough, Tachypnea & Tachycardia 2/2 COVID-19 Viral Syndrome 2. Acute Respiratory Failure with Hypoxia & Hypocapnia 2/2 Covid-19 Viral Pneumonia 3. Acute Tachycardia & Tachypnea in Setting of Acute on Chronic Atrial Fibrillation w/ Flutter, Occasional Rapid Response on Apixaban 4. Acute on Chronic Normocytic Anemia 5. Acute on Chronic Kidney Disease Stage 4 6. Hyperkalemia 7. Hyperchloremia ADDITIONAL DIAGNSES: 8. BPH 9. Hypertension 10. Hx Prostate Cancer 11. Depression 12. Type II diabetes, Diet Controlled 13. GERD 14. Obesity Class 2: BMI 34.0 Hosp. Course includes: Patient's chief symptoms on admission were; hypoxia requiring supplemental oxygen therapy, hypocapnea, tachycardia and tachypnea. Patient noted on file- Moderna vaccination x 3 doses. Supportive care and monitoring implemented; screening/trend labs, EKGs and imaging studies. EKGs obtained during this hospitalization, noted with Atrial flutter with variable A-V block with PVCs. Pt is on chronic anticoagulation with apixiban for management of chronic Atrial Flutter. CXR obtained-impression negative for cardiopulmonary and elevated right diaphragm and possible right lower lobe atelectasis. No evidence of superimposed bacterial pneumonia. Airborne Precautions initiated. COVID-19 viral pneumonia treatment was initiated with ; dexamethasone 6mg qd, PRN acetaminophen/tesselon/albuterol inhaler, continous pox, telemetry monitoring, PRN supplementation of electrolytes, consults, etc. Patient noted with respiratory alkalosis; CO2 levels ranged between 15-20 mmol/L - treated with sodium bicarbonate supplementation of 1300mg oral twice a day for management. Patient did not require remdesivir. Patient considered for discharge on 9/29/22, and initially no labs were obtained. In preparing medication reconcillation, unable to determine if sodium bicarbonate should be ordered on discharge. There fore, ordered a CHEM7 at 13:00 on 9/29/2022. CHEM7 resulted, most notable for hyperkalemia (K+ level of 5.80) and Scr 2.2/BUN 40. NO hemolysis noted on lab report. Discharge cancelled for management of hyperkalemia. One dose of Patiromer Calcium Sorbitex 8.4gm/1PKT was ordered and administered. Telemetry monitoring restarted, EKG obtained at this time(results - Aflutter with variable A-V block, ST & Twave abnormality), initiated IVF hydration w/ NS @ 75cc/hr and cardiac enzymes ordered. On following day (9/30/22), Pt denied any acute concerns or pain, K+ level; 5.0, Scr 2.2 and cardiac enzyme set of 3 negative for troponin elevation. Patient was cleared for discharge to home with family at this time- on 9/30/22.
Age: 91.0
Sex: M
Vaccine: COVID19
Symptoms: White blood cell count increased
Clinical narrative: /Narrative: Pt presented to ED on 9/27/2022 c/o cough with yellow mucous and chest congestion x 1 week; + sick contact exposure. In the ED, the pt was tachypnic. COVID-19 swab was positive. CXR showed elevated right diaphragm and possible right lower lobe atelectasis. Pt admitted 9/27/22-9/30/22 with priniple diagnosis: PRINCIPAL DIAGNOSIS: 1. New Onset of Shortness of Breath with Productive Cough, Tachypnea & Tachycardia 2/2 COVID-19 Viral Syndrome 2. Acute Respiratory Failure with Hypoxia & Hypocapnia 2/2 Covid-19 Viral Pneumonia 3. Acute Tachycardia & Tachypnea in Setting of Acute on Chronic Atrial Fibrillation w/ Flutter, Occasional Rapid Response on Apixaban 4. Acute on Chronic Normocytic Anemia 5. Acute on Chronic Kidney Disease Stage 4 6. Hyperkalemia 7. Hyperchloremia ADDITIONAL DIAGNSES: 8. BPH 9. Hypertension 10. Hx Prostate Cancer 11. Depression 12. Type II diabetes, Diet Controlled 13. GERD 14. Obesity Class 2: BMI 34.0 Hosp. Course includes: Patient's chief symptoms on admission were; hypoxia requiring supplemental oxygen therapy, hypocapnea, tachycardia and tachypnea. Patient noted on file- Moderna vaccination x 3 doses. Supportive care and monitoring implemented; screening/trend labs, EKGs and imaging studies. EKGs obtained during this hospitalization, noted with Atrial flutter with variable A-V block with PVCs. Pt is on chronic anticoagulation with apixiban for management of chronic Atrial Flutter. CXR obtained-impression negative for cardiopulmonary and elevated right diaphragm and possible right lower lobe atelectasis. No evidence of superimposed bacterial pneumonia. Airborne Precautions initiated. COVID-19 viral pneumonia treatment was initiated with ; dexamethasone 6mg qd, PRN acetaminophen/tesselon/albuterol inhaler, continous pox, telemetry monitoring, PRN supplementation of electrolytes, consults, etc. Patient noted with respiratory alkalosis; CO2 levels ranged between 15-20 mmol/L - treated with sodium bicarbonate supplementation of 1300mg oral twice a day for management. Patient did not require remdesivir. Patient considered for discharge on 9/29/22, and initially no labs were obtained. In preparing medication reconcillation, unable to determine if sodium bicarbonate should be ordered on discharge. There fore, ordered a CHEM7 at 13:00 on 9/29/2022. CHEM7 resulted, most notable for hyperkalemia (K+ level of 5.80) and Scr 2.2/BUN 40. NO hemolysis noted on lab report. Discharge cancelled for management of hyperkalemia. One dose of Patiromer Calcium Sorbitex 8.4gm/1PKT was ordered and administered. Telemetry monitoring restarted, EKG obtained at this time(results - Aflutter with variable A-V block, ST & Twave abnormality), initiated IVF hydration w/ NS @ 75cc/hr and cardiac enzymes ordered. On following day (9/30/22), Pt denied any acute concerns or pain, K+ level; 5.0, Scr 2.2 and cardiac enzyme set of 3 negative for troponin elevation. Patient was cleared for discharge to home with family at this time- on 9/30/22.
Age: 82.0
Sex: F
Vaccine: COVID19
Symptoms: Incorrect product formulation administered
Clinical narrative: Patient got monovalent covid vaccine instead of the bivalent covid vaccine for booster dose
Age: 79.0
Sex: M
Vaccine: COVID19
Symptoms: Incorrect product formulation administered
Clinical narrative: Monovalent Vaccine given instead of Bivalent
Sex: M
Vaccine: FLU4
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: Patient was mistakenly give high dose flu vaccine. Not indicated for this age. Sequiris Lot 346336 Exp 5-2023
Sex: F
Vaccine: FLU4
Symptoms: Product administered to patient of inappropriate age, Wrong product administered
Clinical narrative: Patient was mistakenly give high dose flu vaccine. Not indicated for this age. Sequiris Lot 346336 Exp 5-2023
Sex: F
Vaccine: FLU3
Symptoms: Product administered to patient of inappropriate age, Wrong product administered
Clinical narrative: Patient was mistakenly give high dose flu vaccine. Not indicated for this age. Sequiris Lot 346336 Exp 5-2023
Sex: F
Vaccine: FLU4
Symptoms: Incorrect dose administered, Product administered to patient of inappropriate age
Clinical narrative: Patient was mistakenly give high dose flu vaccine. Not indicated for this age. Sequiris Lot 346336 Exp 5-2023
Sex: M
Vaccine: FLU4
Symptoms: Product administered to patient of inappropriate age, Wrong product administered
Clinical narrative: Patient was mistakenly give high dose flu vaccine. Not indicated for this age. Sequiris Lot 346336 Exp 5-2023
Age: 48.0
Sex: F
Vaccine: FLUR4
Symptoms: Erythema, Urticaria
Clinical narrative: I received the FloBloc vaccine from my doctor's office and within 30 minutes, had red bright welts along my neck, shoulder, back and top of chest. It has not been 9 days and there are still marks on my skin. The doctor and a specialist, allergist, were not aware of any side effects and I have no history of allergies to to vaccinations.
Age: 70.0
Sex: M
Vaccine: COVID19-2, FLUA4
Symptoms: Cerumen removal, Eructation, Excessive cerumen production, Headache, Lethargy
Clinical narrative: I was given two vaccines at the same time (FLU VACC 2022-2023 65+ YR, 0.5 ML, IM, ADJUVANTED, QUAD (FLUAD + SARS-COV-2 COVID-19 VACCINE 18+ YRS, BIVALENT 0.5ML, IM, MODERNA BOOSTER) and had/have reactions that continue including burning when breathing deep, lethargy, heart palpitations, and headaches. Vaccinations were given at MD office but given by Medical Assistant before I spoke with the MD. I was assured that two vaccines given at once were OK by the MA even when I questioned how that would be with an Emergency Use Booster. On 9/30/2022 I went to Urgent Care where APN examined me and said with tow vaccines he could not attribute symptoms with one or the other of the vaccines or the combination and to never get two vaccines at once. He noted ear wax blockage and had ears cleaned and prescribed NEO/HC 1% OTIC SOL BLUE drops but ear wax blockage existed before vaccinations. Symptoms continue as of the date of this complaint. Does the FDA allow combination vaccinations with the COVID boosters and if so, under what pretense?
Age: 70.0
Sex: M
Vaccine: COVID19-2, FLUA4
Symptoms: Palpitations
Clinical narrative: I was given two vaccines at the same time (FLU VACC 2022-2023 65+ YR, 0.5 ML, IM, ADJUVANTED, QUAD (FLUAD + SARS-COV-2 COVID-19 VACCINE 18+ YRS, BIVALENT 0.5ML, IM, MODERNA BOOSTER) and had/have reactions that continue including burning when breathing deep, lethargy, heart palpitations, and headaches. Vaccinations were given at MD office but given by Medical Assistant before I spoke with the MD. I was assured that two vaccines given at once were OK by the MA even when I questioned how that would be with an Emergency Use Booster. On 9/30/2022 I went to Urgent Care where APN examined me and said with tow vaccines he could not attribute symptoms with one or the other of the vaccines or the combination and to never get two vaccines at once. He noted ear wax blockage and had ears cleaned and prescribed NEO/HC 1% OTIC SOL BLUE drops but ear wax blockage existed before vaccinations. Symptoms continue as of the date of this complaint. Does the FDA allow combination vaccinations with the COVID boosters and if so, under what pretense?
Sex: F
Vaccine: SMALLMNK
Symptoms: Injection site pain, Injection site pruritus
Clinical narrative: I got the monkeypox vaccine. The site was sore and itchy for 3 weeks.
Sex: F
Vaccine: FLU4
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: Patient was mistakenly give high dose flu vaccine. Not indicated for this age. Sequiris Lot 346336 Exp 5-2023
Age: 75.0
Sex: F
Vaccine: COVID19-2, COVID19-2
Symptoms: Injection site pain, Injection site swelling, Injection site warmth
Clinical narrative: 9/26/2022 I had the appointment and I went there and there was a short wait. And then it was my turn they gave me the shot sitting down. The person giving me the shot sat to my left and there was nothing odd about that. It didn't hurt or anything. It seemed fine. The next day I woke up it was sore and swollen and when I touched it, it was warm and pinkish purple so there was clearly something wrong. I thought that it would go away but when it didn't I went to urgent care 9/29/2022. I called the pharmacy and she asked me some questions and said she would put it in the reporting system and told me to go to urgent care. I tried to see my PCP but they said they could not fit me in so I just went to an urgent care. They asked question and looked at it and suggested I put ice on it and take some ADVIL. I did not take the ADVIL but it did go away in a couple of days.
Age: 75.0
Sex: F
Vaccine: COVID19-2, COVID19-2
Symptoms: Pain in extremity, Peripheral swelling, Skin discolouration, Skin warm
Clinical narrative: 9/26/2022 I had the appointment and I went there and there was a short wait. And then it was my turn they gave me the shot sitting down. The person giving me the shot sat to my left and there was nothing odd about that. It didn't hurt or anything. It seemed fine. The next day I woke up it was sore and swollen and when I touched it, it was warm and pinkish purple so there was clearly something wrong. I thought that it would go away but when it didn't I went to urgent care 9/29/2022. I called the pharmacy and she asked me some questions and said she would put it in the reporting system and told me to go to urgent care. I tried to see my PCP but they said they could not fit me in so I just went to an urgent care. They asked question and looked at it and suggested I put ice on it and take some ADVIL. I did not take the ADVIL but it did go away in a couple of days.
Sex: U
Vaccine: DTPPVHBHPB, PNC13, RV5, RV5, RV5
Symptoms: Expired product administered
Clinical narrative: No additional AE reported; Caller is a nurse reporting that an expired dose of ROTATEQ was administered to the patient on 13SEP2022. Caller confirmed that the ROTATEQ has not been involved in a temperautre excursion through the date of administration. No additional information; This spontaneous report was received from a registered nurse and refers to a patient of unknown age and gender. No information about the patient's pertinent medical history, concurrent conditions, concomitant medications and drug reactions or allergies was provided.  On 13-SEP-2022, the patient was vaccinated with an expired dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) (expired product administered) 2 ml, orally, lot # 1741381 with expiration date of 04-SEP-2022, for prophylaxis.  It was confirmed that the vaccine did not have a previous temperature excursion.        No additional event reporter, no further information provided.
Sex: U
Vaccine: DTPPVHBHPB, PNC13, RV5, RV5, RV5
Symptoms: Expired product administered, No adverse event
Clinical narrative: No additional AE reported; Caller is a nurse reporting that an expired dose of ROTATEQ was administered to the patient on 13SEP2022. Caller confirmed that the ROTATEQ has not been involved in a temperautre excursion through the date of administration. No additional information; This spontaneous report was received from a registered nurse and refers to a patient of unknown age and gender. No information about the patient's pertinent medical history, concurrent conditions, concomitant medications and drug reactions or allergies was provided.  On 13-SEP-2022, the patient was vaccinated with an expired dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) (expired product administered) 2 ml, orally, lot # 1741381 with expiration date of 04-SEP-2022, for prophylaxis.  It was confirmed that the vaccine did not have a previous temperature excursion.        No additional event reporter, no further information provided.
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test, Vaccination site pain
Clinical narrative: A little soreness in the site of injection; 1st dose of Moderna COVID-19 Vaccine on 27Jan2021 and 2nd dose on 8Mar2021; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE PAIN (A little soreness in the site of injection) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1st dose of Moderna COVID-19 Vaccine on 27Jan2021 and 2nd dose on 8Mar2021) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 029A21A and 037K20A) for COVID-19 vaccination.     Concurrent medical conditions included Seasonal allergy, Drug allergy (diabetic medications), Drug allergy (cholesterol medications), Diabetes, Cholesterol, Asthma (acute asthma) and GERD (Intestinal reflux).   On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 08-Mar-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced VACCINATION SITE PAIN (A little soreness in the site of injection). 08-Mar-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1st dose of Moderna COVID-19 Vaccine on 27Jan2021 and 2nd dose on 8Mar2021). On 12-Mar-2021, VACCINATION SITE PAIN (A little soreness in the site of injection) had resolved. At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1st dose of Moderna COVID-19 Vaccine on 27Jan2021 and 2nd dose on 8Mar2021) outcome was unknown.            Patient stated she was under a lot of regular and concomitant medications. No other vaccines were given prior to Moderna COVID-19 vaccine. No treatment drug details were reported.
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Inappropriate schedule of product administration, Vaccination site pain
Clinical narrative: A little soreness in the site of injection; 1st dose of Moderna COVID-19 Vaccine on 27Jan2021 and 2nd dose on 8Mar2021; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE PAIN (A little soreness in the site of injection) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1st dose of Moderna COVID-19 Vaccine on 27Jan2021 and 2nd dose on 8Mar2021) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 029A21A and 037K20A) for COVID-19 vaccination.     Concurrent medical conditions included Seasonal allergy, Drug allergy (diabetic medications), Drug allergy (cholesterol medications), Diabetes, Cholesterol, Asthma (acute asthma) and GERD (Intestinal reflux).   On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 08-Mar-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced VACCINATION SITE PAIN (A little soreness in the site of injection). 08-Mar-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1st dose of Moderna COVID-19 Vaccine on 27Jan2021 and 2nd dose on 8Mar2021). On 12-Mar-2021, VACCINATION SITE PAIN (A little soreness in the site of injection) had resolved. At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1st dose of Moderna COVID-19 Vaccine on 27Jan2021 and 2nd dose on 8Mar2021) outcome was unknown.            Patient stated she was under a lot of regular and concomitant medications. No other vaccines were given prior to Moderna COVID-19 vaccine. No treatment drug details were reported.
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Vaccination site bruising, Vaccination site pain
Clinical narrative: A little soreness in the site of injection; 1st dose of Moderna COVID-19 Vaccine on 27Jan2021 and 2nd dose on 8Mar2021; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE PAIN (A little soreness in the site of injection) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1st dose of Moderna COVID-19 Vaccine on 27Jan2021 and 2nd dose on 8Mar2021) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 029A21A and 037K20A) for COVID-19 vaccination.     Concurrent medical conditions included Seasonal allergy, Drug allergy (diabetic medications), Drug allergy (cholesterol medications), Diabetes, Cholesterol, Asthma (acute asthma) and GERD (Intestinal reflux).   On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 08-Mar-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced VACCINATION SITE PAIN (A little soreness in the site of injection). 08-Mar-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1st dose of Moderna COVID-19 Vaccine on 27Jan2021 and 2nd dose on 8Mar2021). On 12-Mar-2021, VACCINATION SITE PAIN (A little soreness in the site of injection) had resolved. At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1st dose of Moderna COVID-19 Vaccine on 27Jan2021 and 2nd dose on 8Mar2021) outcome was unknown.            Patient stated she was under a lot of regular and concomitant medications. No other vaccines were given prior to Moderna COVID-19 vaccine. No treatment drug details were reported.
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test, Vaccination site pain
Clinical narrative: big bruise that lasted 4 days after the 1st dose; little soreness in the site of injection; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE BRUISING (big bruise that lasted 4 days after the 1st dose) and VACCINATION SITE PAIN (little soreness in the site of injection) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037K20A) for COVID-19 vaccination.     Concurrent medical conditions included Seasonal allergy, Diabetes (no recent changes), Cholesterol (no recent changes), Asthma (Acute asthma, no recent changes) and GERD (intestinal reflux, no recent changes).    On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Jan-2021, the patient experienced VACCINATION SITE BRUISING (big bruise that lasted 4 days after the 1st dose) and VACCINATION SITE PAIN (little soreness in the site of injection). On 31-Jan-2021, VACCINATION SITE BRUISING (big bruise that lasted 4 days after the 1st dose) and VACCINATION SITE PAIN (little soreness in the site of injection) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       Patient stated she was under a lot of regular and concomitant medications, patient was taking diabetic medications, cholesterol medications. No other vaccines was given prior to Moderna COVID-19 vaccine. No treatment drug details was reported.
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Inappropriate schedule of product administration, Vaccination site pain
Clinical narrative: big bruise that lasted 4 days after the 1st dose; little soreness in the site of injection; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE BRUISING (big bruise that lasted 4 days after the 1st dose) and VACCINATION SITE PAIN (little soreness in the site of injection) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037K20A) for COVID-19 vaccination.     Concurrent medical conditions included Seasonal allergy, Diabetes (no recent changes), Cholesterol (no recent changes), Asthma (Acute asthma, no recent changes) and GERD (intestinal reflux, no recent changes).    On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Jan-2021, the patient experienced VACCINATION SITE BRUISING (big bruise that lasted 4 days after the 1st dose) and VACCINATION SITE PAIN (little soreness in the site of injection). On 31-Jan-2021, VACCINATION SITE BRUISING (big bruise that lasted 4 days after the 1st dose) and VACCINATION SITE PAIN (little soreness in the site of injection) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       Patient stated she was under a lot of regular and concomitant medications, patient was taking diabetic medications, cholesterol medications. No other vaccines was given prior to Moderna COVID-19 vaccine. No treatment drug details was reported.
Age: 67.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Vaccination site bruising, Vaccination site pain
Clinical narrative: big bruise that lasted 4 days after the 1st dose; little soreness in the site of injection; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE BRUISING (big bruise that lasted 4 days after the 1st dose) and VACCINATION SITE PAIN (little soreness in the site of injection) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037K20A) for COVID-19 vaccination.     Concurrent medical conditions included Seasonal allergy, Diabetes (no recent changes), Cholesterol (no recent changes), Asthma (Acute asthma, no recent changes) and GERD (intestinal reflux, no recent changes).    On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Jan-2021, the patient experienced VACCINATION SITE BRUISING (big bruise that lasted 4 days after the 1st dose) and VACCINATION SITE PAIN (little soreness in the site of injection). On 31-Jan-2021, VACCINATION SITE BRUISING (big bruise that lasted 4 days after the 1st dose) and VACCINATION SITE PAIN (little soreness in the site of injection) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       Patient stated she was under a lot of regular and concomitant medications, patient was taking diabetic medications, cholesterol medications. No other vaccines was given prior to Moderna COVID-19 vaccine. No treatment drug details was reported.
Age: 72.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: Fever; Dizzy; Sore throat; Headache; Coughing; Congested chest; No interest in eating; Hard to sleep; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 72-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 26Sep2022 at 10:45 as dose 4 (booster), single (Lot number: Gj5342) at the age of 72 years, in right arm for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Past drug history included: Codine, reaction(s): "Known allergies: Codine", notes: Known allergies: Codine. Vaccination history included: BNT162b2 (Prev dose product = COVID 19, Prev dose brand = Pfizer Covid-19 , Prev dose brand unknown = False, Is bivalent = False , Prev dose lot number = EW0191 , Prev dose lot unknown = False, Prev dose administration date = 19Oct2021, Prev dose dose number = 3, Prev dose vaccine location = Right arm), administration date: 19Oct2021, when the patient was 71-year-old, for COVID-19 immunization; Covid-19 vaccine (Primary Immunization series complete; Unknown manufacturer), for COVID-19 immunization. The following information was reported: RESPIRATORY TRACT CONGESTION (non-serious) with onset 28Sep2022 at 01:00, outcome "not recovered", described as "Congested chest"; COUGH (non-serious) with onset 28Sep2022 at 01:00, outcome "not recovered", described as "Coughing"; DIZZINESS (non-serious) with onset 28Sep2022 at 01:00, outcome "not recovered", described as "Dizzy"; PYREXIA (non-serious) with onset 28Sep2022 at 01:00, outcome "not recovered", described as "Fever"; INSOMNIA (non-serious) with onset 28Sep2022 at 01:00, outcome "not recovered", described as "Hard to sleep"; HEADACHE (non-serious) with onset 28Sep2022 at 01:00, outcome "not recovered"; DECREASED APPETITE (non-serious) with onset 28Sep2022 at 01:00, outcome "not recovered", described as "No interest in eating"; OROPHARYNGEAL PAIN (non-serious) with onset 28Sep2022 at 01:00, outcome "not recovered", described as "Sore throat". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of pyrexia, dizziness, oropharyngeal pain, headache, cough, respiratory tract congestion, decreased appetite, insomnia.  Additional information: Fever, dizzy, sore throat, headache, congested chest, coughing, No interest in eating. Got vaccine on Monday 26Sep, by Wednesday all above symptoms, in bed - expecting to get better, hard to sleep, by Friday continued feeling worse, Saturday am, home Covid test was positive. No other vaccine in four weeks. No covid prior vaccination. Covid tested post vaccination on 30Sep2022. Covid test type post vaccination was nasal Swab. Covid test was positive.  Follow-up attempts are completed. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202201197702 same patient, different events after different doses of the vaccine;